Spiros Liras

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2554567/publications.pdf

Version: 2024-02-01

75 papers	6,045 citations	71102 41 h-index	71685 76 g-index
93 all docs	93 docs citations	93 times ranked	7080 citing authors

#	Article	IF	Citations
1	The Future of Peptideâ€based Drugs. Chemical Biology and Drug Design, 2013, 81, 136-147.	3.2	1,483
2	On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nature Chemical Biology, 2011, 7, 810-817.	8.0	318
3	Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium(II) Carboxamide Catalysts. Journal of the American Chemical Society, 1995, 117, 5763-5775.	13.7	227
4	Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophreniaâ€Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).. Journal of Medicinal Chemistry, 2009, 52, 5188-5196.	6.4	195
5	Comparative Î±â€Helicity of Cyclic Pentapeptides in Water. Angewandte Chemie - International Edition, 2014, 53, 6965-6969.	13.8	153
6	Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17504-17509.	7.1	130
7	Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing. Journal of the American Chemical Society, 2018, 140, 6596-6603.	13.7	127
8	Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable. Angewandte Chemie - International Edition, 2014, 53, 12059-12063.	13.8	123
9	Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance. MedChemComm, 2012, 3, 1282-1289.	3.4	120
10	Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A Inhibitorsâ€. Journal of Medicinal Chemistry, 2007, 50, 182-185.	6.4	113
11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. Journal of Medicinal Chemistry, 2015, 58, 4581-4589.	6.4	112
12	Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules. Journal of Medicinal Chemistry, 2017, 60, 1665-1672.	6.4	112
13	Fmoc-Based Synthesis of Disulfide-Rich Cyclic Peptides. Journal of Organic Chemistry, 2014, 79, 5538-5544.	3.2	110
14	Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus. Journal of Medicinal Chemistry, 2012, 55, 1318-1333.	6.4	105
15	Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biology, 2017, 15, e2001882.	5.6	104
16	A Mild Method for the Preparation of 1,3,4-Oxadiazoles: Triflic Anhydride Promoted Cyclization of Diacylhydrazines. Synthetic Communications, 2000, 30, 437-443.	2.1	100
17	Enantio- and Diastereoselectivity in the Intramolecular Cyclopropanation of Secondary Allylic Diazoacetates. Journal of the American Chemical Society, 1994, 116, 4493-4494.	13.7	95
18	Use of 3D Properties to Characterize Beyond Rule-of-5 Property Space for Passive Permeation. Journal of Chemical Information and Modeling, 2012, 52, 882-890.	5.4	90

#	Article	IF	Citations
19	Highly selective enantiomer differentiation in intramolecular cyclopropanation reactions of racemic secondary allylic diazoacetates.. Journal of the American Chemical Society, 1995, 117, 11021-11022.	13.7	88
20	Applications of Vinylogous Mannich Reactions. Total Syntheses of theErgotAlkaloids Rugulovasines A and B and Setoclavine. Journal of the American Chemical Society, 2001, 123, 5918-5924.	13.7	88
21	Donated chemical probes for open science. ELife, 2018, 7, .	6.0	80
22	Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability. European Journal of Medicinal Chemistry, 2015, 97, 202-213.	5.5	76
23	Cyclopropanes as conformationally restricted peptide isosteres. Design and synthesis of novel collagenase inhibitors. Tetrahedron, 1993, 49, 3521-3532.	1.9	75
24	Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyraz (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders. Journal of Medicinal Chemistry, 2012, 55, 9045-9054.	6.4	71
25	Peptide to Peptoid Substitutions Increase Cell Permeability in Cyclic Hexapeptides. Organic Letters, 2015, 17, 2928-2931.	4.6	71
26	Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor. Journal of the American Chemical Society, 2017, 139, 3528-3536.	13.7	71
27	An Approach to the Skeleton of the Securinega Alkaloids. The Total Synthesis of (Â±)-Securinine. Organic Letters, 2001, 3, 703-706.	4.6	70
28	Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy. Journal of Medicinal Chemistry, 2009, 52, 7946-7949.	6.4	67
29	Structural basis for selective stalling of human ribosome nascent chain complexes by a drug-like molecule. Nature Structural and Molecular Biology, 2019, 26, 501-509.	8.2	67
30	Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 InÂVitro. Chemistry and Biology, 2014, 21, 284-294.	6.0	63
31	Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. MedChemComm, 2011, 2, 828.	3.4	62
32	Biaryl-Bridged Macrocyclic Peptides: Conformational Constraint via Carbogenic Fusion of Natural Amino Acid Side Chains. Journal of Organic Chemistry, 2012, 77, 3099-3114.	3.2	55
33	Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed. ACS Medicinal Chemistry Letters, 2014, 5, 1148-1151.	2.8	55
34	Discovery of Potent and Orally Bioavailable Macrocyclic Peptideâ€“Peptoid Hybrid CXCR7 Modulators. Journal of Medicinal Chemistry, 2017, 60, 9653-9663.	6.4	54
35	Medicinal Chemistry Design Principles for Liver Targeting Through OATP Transporters. Current Topics in Medicinal Chemistry, 2013, 13, 857-866.	2.1	51
36	Functionalization of Aromatic Amino Acids via Direct Câˆ’H Activation: Generation of Versatile Building Blocks for Accessing Novel Peptide Space. Organic Letters, 2010, 12, 3870-3873.	4.6	50

#	Article	IF	Citations
37	Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 9055-9068.	6.4	50
38	Enantioselective, rhodium catalyzed intramolecular cyclopropanations of homoallylic diazoacetates.. Tetrahedron Letters, 1992, 33, 6727-6730.	1.4	49
39	Novel applications of vinylogous Mannich reactions. Total synthesis of rugulovasines A and B. Journal of the American Chemical Society, 1993, 115, 10450-10451.	13.7	49
40	Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia. Journal of Medicinal Chemistry, 2011, 54, 4536-4547.	6.4	47
41	Design and Discovery of a Selective Small Molecule Î¼ Opioid Antagonist (2-Methyl-N-((2â€²-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). Journal of Medicinal Chemistry, 2011, 54, 5868-5877.	6.4	46
42	A convergent method for the stereoselective synthesis of trisubstituted alkenes. Journal of Organic Chemistry, 1992, 57, 2523-2525.	3.2	44
43	Novel Approach to the Zaragozic Acids. Enantioselective Total Synthesis of 6,7-Dideoxysqualestatin H5. Journal of Organic Chemistry, 2002, 67, 4200-4208.	3.2	41
44	Organic synthesis using bridgehead carbocations and bridgehead enones. Chemical Reviews, 1989, 89, 1591-1598.	47.7	38
45	Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. Journal of Medicinal Chemistry, 2015, 58, 4080-4085.	6.4	38
46	Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. Journal of Medicinal Chemistry, 2018, 61, 5704-5718.	6.4	37
47	Translational Diffusion of Cyclic Peptides Measured Using Pulsed-Field Gradient NMR. Journal of Physical Chemistry B, 2014, 118, 11129-11136.	2.6	35
48	Liverâ€Targeted Smallâ€Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. Angewandte Chemie - International Edition, 2017, 56, 16218-16222.	13.8	35
49	Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1. MedChemComm, 2014, 5, 1290-1296.	3.4	31
50	PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. Journal of Medicinal Chemistry, 2021, 64, 326-342.	6.4	29
51	Design and Synthesis of Diazatricyclodecane Agonists of the G-Protein-Coupled Receptor 119. Journal of Medicinal Chemistry, 2013, 56, 301-319.	6.4	28
52	Macrocyclizations for Medicinal Chemistry: Synthesis of Druglike Macrocycles by High-Concentration Ullmann Coupling. Journal of Organic Chemistry, 2012, 77, 11079-11090.	3.2	27
53	Permeability of Cyclic Peptide Macrocycles and Cyclotides and Their Potential as Therapeutics. ACS Medicinal Chemistry Letters, 2019, 10, 1026-1032.	2.8	24
54	An Efficient Synthesis of Bridged Heterocycles from an Ir(I) Bis-Amination/Ring-Closing Metathesis Sequence. Organic Letters, 2012, 14, 4802-4805.	4.6	22

#	Article	IF	Citations
55	Chiral Sulfoxide-Induced Single Turn Peptide Î±-Helicity. Scientific Reports, 2016, 6, 38573.	3.3	22
56	Organosilicon radical-induced cyclization reactions. Tetrahedron Letters, 1990, 31, 5265-5268.	1.4	20
57	Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. European Journal of Medicinal Chemistry, 2015, 103, 175-184.	5.5	20
58	Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue. Organic and Biomolecular Chemistry, 2017, 15, 2501-2506.	2.8	20
59	Ring Closing Metathesis Mediated Synthesis of 4a-Aryloxodecahydroisoquinolines, Intermediates in the Preparation of Novel Opiates. Organic Letters, 2001, 3, 3483-3486.	4.6	19
60	Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling. European Journal of Medicinal Chemistry, 2017, 127, 703-714.	5.5	19
61	Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1. Journal of Medicinal Chemistry, 2018, 61, 4635-4640.	6.4	19
62	Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. Journal of Medicinal Chemistry, 2020, 63, 10879-10896.	6.4	19
63	Exploring Aromatic Chemical Space with NEAT: Novel and Electronically Equivalent Aromatic Template. Journal of Chemical Information and Modeling, 2012, 52, 1114-1123.	5.4	16
64	Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence. MedChemComm, 2011, 2, 1001.	3.4	15
65	Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel Î¼ opioid receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 523-526.	2.2	14
66	Biaryl piperidines as potent and selective delta opioid receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 503-507.	2.2	14
67	Synthesis of 4,11-dideoxydaunomycinone by a Claisen/Diels-Alder sequence. Journal of Organic Chemistry, 1989, 54, 3137-3139.	3.2	12
68	Revisiting N-to-O Acyl Shift for Synthesis of Natural Product-like Cyclic Depsipeptides. Organic Letters, 2014, 16, 6088-6091.	4.6	11
69	Truncated Glucagon-like Peptide-1 and Exendin-4 Î±-Conotoxin pl14a Peptide Chimeras Maintain Potency and Î±-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro. Journal of Biological Chemistry, 2016, 291, 15778-15787.	3.4	10
70	A new regiochemical control element for diels-alder reactions. Tetrahedron Letters, 1989, 30, 1907-1908.	1.4	6
71	Enantioselective Hydroarylation of Bridged [3.2.1] Heterocycles: An Efficient Entry into the Homoepibatidine Skeleton. Organic Letters, 2013, 15, 3424-3427.	4.6	4
72	Discovery and pharmacological characterization of a selective delta opiate receptor antagonist (CP-646,777). MedChemComm, 2011, 2, 413.	3.4	3

#	Article	IF	Citations
73	Editorial (Hot Topic:Designing Molecules to Cross Biological Membranes). Current Topics in Medicinal Chemistry, 2013, 13, 775-775.	2.1	3
74	Liverâ€Targeted Smallâ€Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. Angewandte Chemie, 2017, 129, 16436-16440.	2.0	1
75	Receptorâ€Mediated Delivery of CRISPRâ€Cas9 Endonuclease for Cell Type Specific Gene Editing. FASEB Journal, 2018, 32, 649.2.	0.5	0